



116027A9
RECEIVED
SEP 18 2002

ATTORNEY'S DOCKET NO.: 2002850-0024

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Botstein, et al. Examiner:
Serial No.: 09/916,849 Art Unit:
Filed: July 26, 2001
For: BASAL MARKERS IN BREAST CANCER AND RELATED REAGENTS
AND METHODS OF USE THEREOF

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

(Select A, B, C or D below)

- A. ☒ This Information Disclosure Statement has been filed:
1. ☐ within three months of the filing date of the above identified U.S. Patent application other than a continued prosecution application under § 1.53(d);
 2. ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application;
 3. ☒ before the mailing date of the first Office Action on the merits in the above-identified application; or
 4. ☐ before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

No fee or certification is required.

B. ☐ This Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of the first Office Action, but before the mailing date of any of a final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application, and:

(check 1 or 2 below)

1. ☐ The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed, OR
2. ☐ The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that

(check a or b below)

- a. ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- b. ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

C. ☐ This Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and on or before payment of the Issue Fee.

1. The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that:
 - a. ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
 - b. ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement; AND

2. The Petition Fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

D. ☐ This Information Disclosure Statement does not comply with any of the provisions set forth above, or is being submitted after the payment of the issue fee; however, Applicants respectfully request that the Statement be placed in the above-referenced file.

PART II: 37 CFR § 1.98 Content of Information Disclosure Statement:

A. ☒ Applicants hereby make of record in the above-identified application all patents, publications, applications or other information submitted for consideration by the Office listed on the attached form PTO-1449 (modified). The order of presentation of the patents, publications, applications or other information should not be construed as an indication of the importance. Applicants have provided a legible copy of:

- each U.S. patent application publication;
- each U.S. foreign patent;
- each publication or that portion which caused it to be listed;
- each pending U.S. application (including the application specification including the claims and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion); and
- other information or that portion which caused it to be listed.

For each patent, publication, or other information listed that is not in the English language, the following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

Alternatively, if a written English-language translation of a non-English-language document, or portion thereof, if within the possession, or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation is provided herein as identified:

B. [] The Applicants hereby make the following additional information of record in the above-identified application:

PART IV: Remarks

A copy of each of the above-identified U.S. and foreign patent(s), publication(s), application(s) or other information submitted is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s), publication(s), application(s), or other information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited materials. An early and favorable action is hereby requested.

Respectfully submitted,

Monica R. Gerber

Monica R. Gerber, M.D., Ph.D.

Registration Number 46,724

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000

Date: 9/12/02

3429722_1.DOC

I hereby certify that this correspondence is being
deposited with the United States Postal service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on 9-12-02

Jennifer Saccoccia

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket: 2002850-0024		In re Application No. 09/916,849	
		Applicant: Botstein, et al.		RECEIVED SEP 18 2002	
		Filing Date: July 26, 2001			
U.S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
U.S. PATENT APPLICATIONS					
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
OTHER DOCUMENTS					
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Aas, et al., "Specific P53 Mutations are Associated with De Novo Resistance to Doxorubicin in Breast Cancer Patients", <i>Nat. Med.</i> 2: 811-814, 1996.				
	Abbas, A. K., Lichtman, A. H. & Pober, J. S. Cellular and Molecular Immunology (Saunders, Philadelphia, 1991.				
	Alizadeh, et al., "Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling", <i>Nature</i> , 403(6769): 503-511, 2000.				
	Alon, et al., "Broad Patterns of Gene Expression Revealed by Clustering Analysis of Tumor and Normal Colon Tissues Probed by Oligonucleotide Arrays", <i>Proc. Natl. Acad Sci USA</i> , 96: 6745-6750, 1999.				
	Anderson, et al., "Prognostic Significance of TP53 Alterations in Breast Carcinoma", <i>Br J. Cancer</i> , 68:540-548, 1993.				
	Baxa, C. A. et al. Human Adipocyte Lipid-Binding Protein: Purification of the Protein and Cloning of its Complementary DNA", <i>Biochemistry</i> , 28:8683-8690, 1989.				
	Berns, E. M. et al. Prevalence of Amplification of the Oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors", <i>Eur J Cancer</i> , 28, 697-700, 1992.				
	Bhargava, V., Kell, D. L., van de Rijn, M. & Warnke, R. A. Bcl-2 Immunoreactivity in Breast Carcinoma Correlates with Hormone Receptor Positivity" <i>Am J Pathol</i> , 145:535-540, 1994.				
	Cahill, et al., "Mutations of Mitotic Checkpoint Genes in Human Cancers, <i>Nature</i> , 392, 300-303, 1998.				
	Cho, et al., "A Genome-Wide Transcriptional Analysis of the Mitotic Cell Cycle", <i>Mol Cell</i> ,				

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket: 2002850-0024	In re Application No. 09/916,849
	Applicant: Botstein, et al. Filing Date: July 26, 2001	
	Group: SEP 1 8 2002	

O I P E
 SEP 1 6 2002
 PATENT AND TRADEMARK OFFICE

RECEIVED
 SEP 1 8 2002

TECH CENTER 1600/2900

	2:65-73, 1998.
	Chu, et al., "The Transcriptional Program of Sporulation in Budding Yeast", <i>Science</i> , 282 : (5393): 1421, 1998, <i>Science</i> , 282 : 699-705, 1998.
	Dairkee, S. H., Mayall, B. H., Smith, H. S. & Hackett, A. J. Monoclonal marker that predicts early recurrence of breast cancer", <i>Lancet</i> , 1:514, 1987.
	Dairkee, S. H., Puett, L. & Hackett, A. J. Expression of Basal and Luminal Epithelium-Specific Keratins in Normal, Benign, and Malignant Breast Tissue", <i>J Natl Cancer Inst</i> , 80 :691-695, 1988.
	DeRisi, et al., "Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale", <i>Science</i> , 278 : 680-686, 1997.
	Eisen, et al., "DNA Arrays for Analysis of Gene Expression", <i>Methods Enzymol</i> , 303 , 179-205, 1999.
	Eisen, et al., "Cluster Analysis and Display of Genome-Wide Expression Patterns", <i>Proc. Natl. Acad Sci USA</i> , 95 : 14863-14868, 1998.
	Fambrough, et al., "Diverse Signaling Pathways Activated by Growth Factor Receptors Induce Broadly Overlapping, Rather than Independent, Sets of Genes", <i>Cell</i> , 97 :727-741, 1999.
	Galitski, et al., "Ploidy Regulation of Gene Expression", <i>Science</i> , 285 :251-254, 1999.
	Golub, et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> , 286 : 531-537, 1999.
	Guelstein, V. I. et al. Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer" <i>Int J Cancer</i> , 42 , 147-153, 1988.
	Guerin, M., Barrois, M., Terrier, M. J., Spielmann, M. & Riou, G. Overexpression of Either c-myc or c-erbB-2/Neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis, <i>Oncogene Res</i> , 3 : 21-31, 1988.
	Gusterson, B. A. et al. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases", <i>Cancer Res</i> , 42 :4763-4770 1982.
	Heintz, N. H., Leslie, K. O., Rogers, L. A. & Howard, P. L. Amplification of the c-erb B-2 Oncogene and Prognosis of Breast Adenocarcinoma", <i>Arch Pathol Lab Med</i> , 114 :160-163, 1990.
	Hoch, R. V., Thompson, D. A., Baker, R. J. & Weigel, R. J. GATA-3 is Expressed in Association with Estrogen Receptor in Breast Cancer" <i>Int J Cancer</i> , 84 :122-128, 1999.
	Iyer, et al., "The Transcriptional Program in the Response of Human Fibroblasts to Serum", <i>Science</i> , 283 : 83-87, 1999.
	Khan, et al., "Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays", <i>Cancer Res</i> , 58 : 5009-5013, 1998.
	Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C. & Harris, A. L. bcl-2 in Normal Human Breast and Carcinoma, Association with Oestrogen Receptor-Positive, Epidermal Growth

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of
Commerce
Patent and Trademark OfficeAtty. Docket:
2002850-0024In re Application No.
09/916,849

Applicant: Botstein, et al.

Filing Date:
July 26, 2001

Group: SEP 18 2002

RECEIVED

TECH CENTER 1600/2900

Factor Receptor-Negative Tumours and in Situ Cancer", *Br J Cancer*, 69:135-139, 1994.Lengauer, et al., "Genetic Instabilities in Human Cancers", *Nature Genetics*, 24(3):227-235, 2000.Li, et al., "Identification of a Human Mitotic Checkpoint Gene: hsMAD2", *Science*, 274: 246-248, 1996.Malzahn, K., Mitze, M., Thoenes, M. & Moll, R. Biological and Prognostic Significance of Stratified Epithelial Cytokeratins in Infiltrating Ductal Breast Carcinomas", *Virchows Arch*, 433: 119-129, 1998.Miettinen, M., Lindenmayer, A. E. & Chaubal, A. Endothelial Cell Markers CD31, CD34, and BNH9 Antibody to H- and Y- Antigens--Evaluation of Their Specificity and Sensitivity in the Diagnosis of Vascular Tumors and Comparison with Von Willebrand Factor", *Mod Pathol*, 7:82-90 1994.Moog-Lutz, C. et al. MLN64 Exhibits Homology with the Steroidogenic Acute Regulatory Protein (STAR) and is Over-Expressed in Human Breast Carcinomas" *Int J Cancer*, 71:183-191, 1997.Nagle, R. B. et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells", *J Histochem Cytochem*, 34:869-881 1986.Osborne, et al., "The Value of Estrogen and Progesterone Receptors in the Treatment of Breast Cancer", *Cancer*, 46: 2884-2888, 1980.Pauletti, G., Godolphin, W., Press, M. F. & Slamon, D. J. Detection and Quantitation of HER-2/neu Gene Amplification in Human Breast Cancer Archival Material using Fluorescence in Situ Hybridization", *Oncogene*, 13:63-72, 1996.Perou, et al., "Distinctive Gene Expression Patterns in Human Mammary Epithelial Cells and Breast Cancers". *Proc. Natl Acad Sci USA*, 96:9212-9217, 1999.Pollack, J. R. et al. Genome-Wide Analysis of DNA Copy-Number Changes Using cDNA Microarrays", *Nat Genet*, 23: 41-46, 999.Prud'homme, J. F. et al. Cloning of a Gene Expressed in Human Breast Cancer and Regulated by Estrogen in MCF-7 cells", *Dna* 4:11-21, 1985.Ronnov-Jessen, et al., "Cellular Changes Involved in Conversion of Normal to Malignant Breast; Importance of the Stromal Reaction", *Physiol. Rev*, 76:69-125, 1996.Ross, et al., "Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines", *Nature Genetics*, 24(3):227-235, 2000.Slamon, et al., "Studies of the HER-2/Neu Proto-Oncogene In Human Breast and Ovarian Cancer", *Science*, 244: 707-712, 1989.Stein, D. et al. The SH2 Domain Protein GRB-7 is Co-amplified, Overexpressed and in a Tight Complex with HER2 in Breast Cancer", *Embo*, J13: 1331-1340, 1994.Spellman, PT, et al., Comprehensive identification of cell cycle-regulated genes of the yeast *Saccharomyces cerevisiae* by microarray hybridization, *Mol Biol Cell*, 9(12):3273-97, 1998.



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002850-0024	In re Application No. 09/916,849
(REV. 8-83)		Applicant: Botstein, et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: July 26, 2001	Group:
	Tavassoli, et al., "Pathology of the Breast", (Elsevier, New York, 1992).		
	Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I. & Spiegelman, B. M. mPPAR Gamma 2: Tissue-Specific Regulator of an Adipocyte Enhancer", <i>Genes Dev</i> , 8:1224-1234, 1994.		
	Wang, K. et al., Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, <i>Gene</i> , 229:101-108, 1999.		
	Wolf, G. et al. Prognostic Significance of Polo-Like Kinase (PLK) Expression in Non-Small Cell Lung Cancer. <i>Oncogene</i> , 14: 543-549 1997.		
	Yang, G. P., Ross, D. T., Kuang, W. W., Brown, P. O. & Weigel, R. J. Combining SSH and cDNA Microarrays for Rapid Identification of Differentially Expressed Genes", <i>Nucleic Acids Res</i> 27:1517-1523, 1999.		
	Zhou, H. et al. Tumour Amplified Kinase STK15/BTAK Induces Centrosome Amplification, Aneuploidy and Transformation". <i>Nat Genet</i> , 20: 189-193, 1998.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

3429721_1.DOC